Immunotherapy plays an essential role in the treatment of bladder cancer (BC), such as intravesical instillation of Bacillus Calmette-Guerin (BCG) and anti-PD1 immune checkpoint inhibitors. More recently, novel therapies have been applied and made revolutionary progress in the treatment of BC, including antibody-Drug Conjugates (ADC), oncolytic virus, and TCR-T cell therapy. However, even if treatment is constantly updated, only a small number of patients can really benefit, which may be due to the great heterogeneity of the local tumor immune microenvironment among individual patients. Thus, it's important to clarify the role the tumor immune micro-environment plays in these novel therapies, and whether the immune micro-environment related index, such as immune-score or tertiary lymphoid structure, can be applied as the prediction indicators of these novel therapies.
This Research Topic focuses on the role of the tumor immune micro-environment in several therapies of bladder cancer, especially in ADC, oncolytic virus, and TCR-T cell therapy. As there is an exigent need to distinguish which patients will benefit from these therapies before treatment, the articles in this Research Topic should help clinicians and researchers understand more about the role of tumor micro-environment in different therapies in bladder cancer, and may contribute to the discovery of novel immunotherapy targets and knowledge about novel immunity molecular typing.
We welcome articles covering the following topics:
1. The novel immunity molecular typing associated with the immunotherapy in bladder cancer.
2. The changes of tumor immune micro-environment before and after different types of therapies, such as immunotherapy, ADC therapy, and oncolytic virus in bladder cancer
3. The role of tertiary lymphoid structures during different type of therapies in bladder cancer.
4. The application of tumor immune micro-environment related indexes as the companion diagnostic technology of these therapies in bladder cancer
5. The prediction model to predict the overall survival or predict the drug response to the above therapies in bladder cancer
6. The typical case-report or case-series treated by the above therapies which can enlighten clinical medication
Immunotherapy plays an essential role in the treatment of bladder cancer (BC), such as intravesical instillation of Bacillus Calmette-Guerin (BCG) and anti-PD1 immune checkpoint inhibitors. More recently, novel therapies have been applied and made revolutionary progress in the treatment of BC, including antibody-Drug Conjugates (ADC), oncolytic virus, and TCR-T cell therapy. However, even if treatment is constantly updated, only a small number of patients can really benefit, which may be due to the great heterogeneity of the local tumor immune microenvironment among individual patients. Thus, it's important to clarify the role the tumor immune micro-environment plays in these novel therapies, and whether the immune micro-environment related index, such as immune-score or tertiary lymphoid structure, can be applied as the prediction indicators of these novel therapies.
This Research Topic focuses on the role of the tumor immune micro-environment in several therapies of bladder cancer, especially in ADC, oncolytic virus, and TCR-T cell therapy. As there is an exigent need to distinguish which patients will benefit from these therapies before treatment, the articles in this Research Topic should help clinicians and researchers understand more about the role of tumor micro-environment in different therapies in bladder cancer, and may contribute to the discovery of novel immunotherapy targets and knowledge about novel immunity molecular typing.
We welcome articles covering the following topics:
1. The novel immunity molecular typing associated with the immunotherapy in bladder cancer.
2. The changes of tumor immune micro-environment before and after different types of therapies, such as immunotherapy, ADC therapy, and oncolytic virus in bladder cancer
3. The role of tertiary lymphoid structures during different type of therapies in bladder cancer.
4. The application of tumor immune micro-environment related indexes as the companion diagnostic technology of these therapies in bladder cancer
5. The prediction model to predict the overall survival or predict the drug response to the above therapies in bladder cancer
6. The typical case-report or case-series treated by the above therapies which can enlighten clinical medication
